Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
33 hedge funds and large institutions have $47.2M invested in Sinovac Biotech, Ltd in 2013 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
197% more call options, than puts
Call options by funds: $386K | Put options by funds: $130K
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $14.1K | +$13.4K | +3,600 | New |
|
|
U
27
UBS
Zurich,
Switzerland
| $10K | +$9.91K | +2,664 | New |
|
28
Barclays
London,
United Kingdom
| $4K | +$3.65K | +980 | New |
|
|
MFS
29
MSI Financial Services
Springfield,
Massachusetts
| $4K | +$3.72K | +1,000 | New |
|
30
Wells Fargo
San Francisco,
California
| $3K | +$2.79K | +750 | New |
|
31
Ameriprise
Minneapolis,
Minnesota
| $1K | +$744 | +200 | New |
|
|
AA
32
Apriem Advisors
Irvine,
California
| $1K | +$1.12K | +300 | New |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$361 | +97 | New |
|
SVA Hedge Fund Activity: Q2 2013 in Review
33 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2013, worth a combined $47.2M.
Buyers outnumbered sellers: 33 funds opened new SVA positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
- 33 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $47.2M of Sinovac Biotech, Ltd stock for Q2 2013.
- 33 funds opened new Sinovac Biotech, Ltd positions in Q2 2013 and 0 closed out, a net change of +33 holders.
Based on aggregated 13F filings for Q2 2013.